Telithromycin in the treatment of acute bacterial sinusitis, acute exacerbations of chronic bronchitis, and community-acquired pneumonia

about

Telithromycin in the treatment of acute bacterial sinusitis, acute exacerbations of chronic bronchitis, and community-acquired pneumonia

Item

http://www.wikidata.org/entity/Q37116814

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on March 2006

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Telithromycin in the treatment ...... d community-acquired pneumonia

@en

Telithromycin in the treatment ...... community-acquired pneumonia.

@nl

type

Item

label

Telithromycin in the treatment ...... d community-acquired pneumonia

@en

Telithromycin in the treatment ...... community-acquired pneumonia.

@nl

prefLabel

Telithromycin in the treatment ...... d community-acquired pneumonia

@en

Telithromycin in the treatment ...... community-acquired pneumonia.

@nl

P1476

Telithromycin in the treatment ...... d community-acquired pneumonia

@en

P2093

Aleksandra Wierzbowski

http://www.w3.org/2001/XMLSchema#string

Daryl J Hoban

http://www.w3.org/2001/XMLSchema#string

Tamiko Hisanaga

http://www.w3.org/2001/XMLSchema#string

P2860

Efficacy and safety of telithromycin 800 mg once daily for 7 days in community-acquired pneumonia: an open-label, multicenter study.

The complete atomic structure of the large ribosomal subunit at 2.4 A resolution

Structural basis for the interaction of antibiotics with the peptidyl transferase centre in eubacteria

A ketolide resistance mutation in domain II of 23S rRNA reveals the proximity of hairpin 35 to the peptidyl transferase centre.

Bronchopulmonary disposition of the ketolide telithromycin (HMR 3647).

Pharmacokinetics of the new ketolide telithromycin (HMR 3647) administered in ascending single and multiple doses.

In vivo efficacy of the new ketolide telithromycin (HMR 3647) in murine infection models.

Pharmacokinetics and absolute oral bioavailability of an 800-mg oral dose of telithromycin in healthy young and elderly volunteers.

Comparative in vitro activity of telithromycin and beta-lactam antimicrobials against bacterial pathogens from community-acquired respiratory tract infections: data from the first year of PROTEKT (1999-2000).

Susceptibilities of penicillin- and erythromycin-susceptible and -resistant pneumococci to HMR 3647 (RU 66647), a new ketolide, compared with susceptibilities to 17 other agents

P304

59-75

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

George G Zhanel

P577

2006-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18360582

http://www.w3.org/2001/XMLSchema#string

P921

Bruschtfiewer

P932

1661642

http://www.w3.org/2001/XMLSchema#string